Table 1 Baseline characteristics of patients undergoing testing with suspected COVID-19

Age, years

68 (53, 80)

71 (57, 82)

67 (51, 78)

< 0.001

Sex

0.078

 Men

731 (53%)

281 (57%)

450 (52%)

 Women

637 (47%)

215 (43%)

422 (48%)

Ethnicity

0.83

 White

1087 (97%)

372 (97%)

715 (98%)

 Other

29 (2.6%)

11 (2.9%)

18 (2.5%)

Deprivation^b

0.002

 1 (most deprivation)

239 (18%)

65 (13%)

174 (20%)

 2

321 (24%)

116 (24%)

205 (24%)

 3

236 (17%)

79 (16%)

157 (18%)

 4

243 (18%)

93 (19%)

150 (17%)

 5 (least deprivation)

319 (23%)

139 (28%)

180 (21%)

Duration of symptoms, days

3.0 [1.0–5.0]

3.0 [2.0–7.0]

2.0 [1.0–4.0]

< 0.001

 Fever

691 (51%)

322 (65%)

369 (42%)

< 0.001

 Upper respiratory tract symptoms

141 (10%)

63 (13%)

78 (9%)

0.034

 Lower respiratory tract symptoms

891 (65%)

419 (85%)

472 (54%)

< 0.001

 Systemic symptoms

501 (37%)

257 (52%)

244 (28%)

< 0.001

 Neurological symptoms

309 (23%)

118 (24%)

191 (22%)

0.45

 Gastrointestinal symptoms

316 (23%)

107 (22%)

209 (24%)

0.36

 Lymphopenia

894 (65%)

406 (82%)

488 (56%)

< 0.001

 Inflammation

986 (72%)

421 (86%)

565 (65%)

< 0.001

 Radiological signs

409 (30%)

316 (64%)

93 (11%)

< 0.001

 Diabetes mellitus

251 (18%)

96 (19%)

155 (18%)

0.51

 Ischemic heart disease

136 (10%)

45 (9.1%)

91 (11%)

0.44

 Heart failure

112 (8.3%)

38 (7.7%)

74 (8.6%)

0.62

 Stroke

82 (6.0%)

27 (5.4%)

55 (6.3%)

0.60

 COPD

206 (15%)

58 (12%)

148 (17%)

0.011

 Asthma

113 (8.3%)

30 (6.0%)

83 (9.5%)

0.033

 Liver cirrhosis

27 (2.0%)

8 (1.6%)

19 (2.2%)

0.60

 End stage kidney disease

25 (1.8%)

12 (2.4%)

13 (1.5%)

0.31

 ACE inhibitors or ARBs

336 (25%)

129 (26%)

207 (24%)

0.38

 Corticosteroids

223 (16%)

73 (15%)

150 (17%)

0.27

 Immunosuppressants

34 (2.5%)

15 (3.0%)

19 (2.2%)

0.43